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INTRODUCTION
Gastric cancer (GC) is one of the most frequently encoun-
tered malignancies in the world, and has a high prevalence in
Korea. Despite the high incidence of this condition, the genet-
ic events which result in gastric malignancy and the genetic
components which are altered during the inception and natural
history of the neoplasm have yet to be elucidated in detail (1).
Chromosome-based comparative genomic hybridization
(CGH) enables a genome-wide analysis of DNA sequence
copy numbers within in a single experimental procedure, and
has previously uncovered crucial information regarding the
chromosomal changes inherent in a variety of tumors (2, 3).
Several chromosomal regions in which gains or losses are fre-
quently encountered have been identified in both premalig-
nant gastric lesions and gastric adenocarcinomas, using chro-
mosome-based CGH (4-7), thereby suggesting that compli-
cated genetic alterations are a component of the process of
gastric carcinogenesis. However, conventional CGH provides
no information which is sufficiently precise to enable the flag-
ging of the exact locations of oncogenes or tumor suppressor
genes (1). This may be attributable to the relatively low res-
olution which is currently achievable by chromosomal CGH
assays, and in addition CGH data tend to be less suitable for
quantitative analyses, such as genomic tumor profiling (8). 
Hybridization to an array of mapped DNA sequences may
sometimes alleviate the limitations associated with conven-
tional CGH. Hybridization other advantages over conven-
tional CGH, as well as over other currently-employed screen-
ing and diagnostic methods. Copy number alterations detect-
ed by array CGH can be related directly to the sequence infor-
mation, and these results in a dramatic increase in the speed
with which novel cancer-causing genes can be identified (9).
It also enables the high-throughput quantitative measure-
ment of high-resolution DNA copy number changes throu-
ghout the entirety of the genome (10), and constitutes a sig-
nificant advance in identifying piece of knowledge in the hunt
for genes associated with solid tumors (1, 11). More recently,
several cDNA and oligo-based transcript-centric array-CGH
methods have been employed in an attempt to profile a vari-
ety of cancers, including gastric cancer (12). The measurement
of gene label copy number variations might be achieved thro-
ugh the use of these types of arrays. However, genomic aber-
rations on the scale of the entire chromosomal structure, in-
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Genetic Alterations in Primary Gastric Carcinomas Correlated with 
Clinicopathological Variables by Array Comparative Genomic
Hybridization
Genetic alterations have been recognized as an important event in the carcinogen-
esis of gastric cancer (GC). We conducted high resolution bacterial artificial chromo-
some array-comparative genomic hybridization, to elucidate in more detail the ge-
nomic alterations, and to establish a pattern of DNA copy number changes with dis-
tinct clinical variables in GC. Our results showed some correlations between novel
amplified or deleted regions and clinical status. Copy-number gains were frequent-
ly detected at 1p, 5p, 7q, 8q, 11p, 16p, 20p and 20q, and losses at 1p, 2q, 4q, 5q,
7q, 9p, 14q, and 18q. Losses at 4q23, 9p23, 14q31.1, or 18q21.1 as well as a gain
at 20q12 were correlated with tumor-node-metastasis tumor stage. Losses at 9p23
or 14q31.1 were associated with lymph node status. Metastasis was determined
to be related to losses at 4q23 or 4q28.2, as well as losses at 4q15.2, 4q21.21, 4q
28.2, or 14q31.1, with differentiation. One of the notable aspects of this study was
that the losses at 4q or 14q could be employed in the evaluation of the metastatic
status of GC. Our results should provide a potential resource for the molecular cyto-
genetic events in GC, and should also provide clues in the hunt for genes associ-
ated with GC.
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cluding the segmental duplicated, intergenic, subtelomeric,
and telomeric regions, all of which may perform critical func-
tions in the development and progression of cancers, may be
greatly minimized with the use of these techniques (13). In
order to ameliorate these inherent limitations, some resear-
chers have begun to employ bacterial artificial chromosome
(BAC)/PAC-based array-CGH methods, enabling them to
conduct effective comparisons of clinically relevant genomic
aberrations throughout the entirety of the genome (10). There
have been a few previous studies which have focused on the
characterization of chromosomal alterations in GC by array-
CGH, but the molecular events which culminate in gastric
malignancy, as well as the clinical correlations between these
aberrations and the events comprising these conditions, remain
to be clearly elucidated.
The purpose of this study was, firstly, to screen for changes
in DNA copy numbers, and to identify smaller chromosomal
changes in cases of gastric adenocarcinoma, using high reso-
lution BAC array-CGH and, secondly, to establish patterns
of DNA copy number changes which can be associated with
distinct clinical variables.
MATERIALS AND METHODS
Clinical sample preparation 
Twenty-eight gastric adenocarcinoma patients were studied
for array CGH. Fresh tissues were obtained from the operat-
ing room of the Department of General Surgery at Chung-
nam National University Hospital in Daejon, Korea. All
clinical data is shown in Table 1. All the patients were clas-
sified according to the WHO histological typing of gastric
tumors and the UICC tumor-node-metastasis (TNM) stag-
ing system. The demographic and pathological data, includ-
ing age, gender, the site of the tumor and the tumor stage
were obtained by a review of the medical records.
Genomic DNA Isolation
DNA was extracted from fresh frozen tissues of advanced
gastric cancer and microdissected cells from early gastric can-
cer. Tumor cells were separated by manual microdissection of
10 m frozen tissue sections stained with hematoxyhin-eosin.
Tumor areas with an estimated content of 70% or more tumor
cells were microdissected using a sharp scalpel under the di-
rection of a pathologist. The genomic DNA was extracted
using a Genomic DNA purification kit (Promega, Madison,
WI, U.S.A.). The detailed procedure of the DNA extraction
in chronological order was digesting the frozen tissue or mi-
crodissected cells with a lysis buffer, adding 10 mg/mL pro-
teinase K, incubating the samples overnight at 55℃, remov-
ing the RNA with RNAse, precipitating the unnecessary
proteins, aliquoting the DNA from the supernatants followed
by washing and suspending the DNA.
Construction of BAC library
BAC clones were selected from Macrogen’s proprietary BAC
library (http://www. macrogen.com). Briefly, pECBAC1 (Fri-
jters et al. 1997) was restricted with HindIII and size select-
ed male DNA were used to generate a BAC library. The vec-
tors for this library were transformed and grown in DH10B.
Construction of BAC-mediated array CGH microarray
The clones were first selected bioinformatically to give an
average genomic coverage of 2 Mb resolutions. All of the clo-
nes were two end-sequenced using Applied Biosystems 3,700
sequencers and their sequences were blasted and mapped ac-
cording to their positions on the UCSC human genome data-
base (http://www.genome.ucsc.edu). These clones were pre-
M, male; F, female; EGC, early gastric cancer; AGC, advanced gastric
cancer; WD, well differentiated; MD, moderately differentiated; PD, poor-
ly differentiated. Alterations were defined by log 2 ratio thresholds of 0.25
for copy number gain, -0.25 for loss. 
*Gained clone No., cases with copy number gain; 
� Lost clone No., cases
with copy number lost.
1 62 M AGC IV PD + + 42 32
2 78 F AGC III PD + - 47 87
3 75 M AGC II PD -- 84 36
4 62 M AGC I PD -- 21 21
5 74 F AGC II MD + - 93 53
6 71 M AGC II MD -- 57 6
7 73 M AGC II MD -- 51 12
8 78 M AGC III WD + - 35 5
9 77 M AGC II MD -- 24 16
10 62 M AGC II PD + - 66 20
11 40 F AGC II PD + - 119 21
12 72 M AGC III PD + - 108 25
13 88 M AGC III MD + - 115 26
14 52 M AGC I WD - +5 5 2 4
15 73 M AGC III MD + - 92 51
16 52 M AGC II MD -- 122 24
17 58 M AGC II MD -- 91 2
18 61 M AGC III PD + - 147 117
19 75 M AGC III PD + - 13 41
20 59 F EGC I PD -- 12 1
21 80 M AGC II PD + - 155 1
22 89 M AGC IV PD + + 129 244
23 64 F AGC I WD -- 5 109
24 65 M EGC I PD -- 71 5
25 61 M AGC I MD -- 142 122
26 78 F AGC IV PD + + 221 322
27 75 M AGC I MD -- 36 17
28 83 M AGC I PD + - 43 12
Table 1. Clinico-pathological data and array CGH results of 28
gastric adenocarcinomas 
No.
Age
(yr)
Sex
TNM
stage
WHO
differen-
tiation
Lymph
node
Meta-
stasis
No. of
�
lost 
clones 
Borr-
mann’s 
type
No. of*
gained 
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pared by conventional alkaline lysis method to obtain BAC
DNA. The DNA was sonicated to generate about 3 kb frag-
ments before mixing with 50% DMSO spotting buffer. The
arrays were manufactured by GeneMachine’s OmniGrid100
using 24 pin format. BAC clones were represented on an array
as triplicated spots and each array was pre-scanned using an
Axon scanner for a proper spot morphology. The array used
in this study consists of 1,440 human BACs, which were
spaced approximately 2.3 Mb across the whole genome.
DNA labeling for array CGH
The labeling and hybridization protocols described by Pin-
kel et al. (15) were used, with some modifications. Briefly,
21  L of solution containing 500 ng of normal DNA (refer-
ence) or tumor DNA (test), 20  L of BioPrime
� DNA Label-
ing System random primers solution (Invitrogen, San Diego,
CA, U.S.A.) and water were combined and incubated for 5
min at 95℃, and subsequently cooled on ice. After the addi-
tion of 5  L of 10× dNTPs labeling mix (1 mM dCTP, 2
mM dATP, 2 mM dGTP, 2 mM dTTP), 3  L of 1 mM Cy-
3 or Cy-5 dCTP (GeneChem, Seoul, Korea) and 40 U of Bio-
Prime
� DNA Labeling System Klenow fragment (Invitro-
gen), the mixture was gently mixed and incubated overnight
at 37℃. The addition of 5  L of BioPrime
� DNA Labeling
System Stop Buffer (Invitrogen) ended the reaction. After label-
ing, unincorporated fluorescent nucleotides were removed
by use of QIAquick Spin columns (QIAGEN, Valencia, CA,
U.S.A.). In one tube, Cy3-labeled sample and Cy5-labeled
reference DNAs were mixed together, and 50  g of human
Cot I DNA (Invitrogen) 20  L of 3 M sodium acetate and
600  L of cold 100% ethanol were precipitated.
Array hybridization, imaging and data analysis
The pellet was resuspended in 40  L of a hybridization solu-
tion containing 50% formamide, 10% dextran sulfate, 2×
SSC, 4% SDS and 200  g yeast tRNA. The hybridization sol-
ution was denatured for 10 min at 72℃ and was incubated
subsequently for 1 hr at 37℃, to allow blocking of repetitive
sequence. Hybridization was performed in slide chambers for
48 hr at 37℃. After post hybridization washes, arrays were
rinsed, dried with spin, and scanned into two 16-bit TIFF im-
age files using GenePix4200A two-color fluorescent scanner
(Axon Instruments, Sunnyvale, CA, U.S.A.) and quantitated
using GenePix software (Axon Instruments, Sunnyvale, CA
U.S.A.). The log 2 transformed fluorescent ratios were calcu-
lated from background subtracted median intensity values,
and these values were normalized according to the intensity
normalization method. Chromosomal aberrations were catego-
rized as a gain when the normalized log 2 transformed fluores-
cent ratio was higher than 0.25 and as a loss when this ratio
was below -0.25. These two threshold values were chosen
empirically by selecting a 3×SD value calculated from 30
normal male to normal female hybridization experiments.
Real-time reverse transcription-PCR analysis
For validation of microarray data, we conducted real-time
quantitative reverse transcription-PCR (RT-PCR) using 28
gastric carcinomas, which had been used in the array-CGH
experiment. Two genes were randomly selected from among
the group of genes which had significant correlation with
clinicopathological parameters. These genes were as follows:
MAFB at 20q12, and were used for array-CGH experiment.
Two genes were randomly selected from among the group of
genes which had been correlated significantly with clinico-
pathological parameters. These genes were as follows: MAFB
at 20q12, TSHR at 14q31.1. The gene copy number of known
genes MAFB and TSHR was determined in the tumor sam-
ples with the following primers set for the 5′ forward primer:
GCTAAGCCTCTCACCCTAGGA and the 3′ reverse primer:
CCCTGAGGTCCCTTCTGAAC and the 5′ forward primer:
GGATCCCAAAGGGCTCCAT and the 3′ reverse primer:
AAGATGGTTGAAAACT-GGACTTCTGT respectively
according to a previously described protocol with normaliz-
ing normal human pooled genomic DNA (Promega, Madi-
son, WI, U.S.A.) as a calibrator sample. 
RT-PCR reactions were performed on an ABI 7900 HT
(Applied Biosystems, Foster City, CA, U.S.A.). Amplification
mixtures (20  L) contained template DNA (approximately
2 ng), 1× TaqMan PCR MasterMix (Applied Biosystems,
Foster City, CA, U.S.A.) and 900 nM of each primer. The
cycling conditions comprised 10 min polymerase activation
at 95℃, 40 cycles at 95℃for 15 sec and 60℃for 1 min. The
relative copy numbers of the selected genes were determined
in the tumor samples and on three normal control DNAs
using the above listed primer pairs according to the manu-
facturer’s protocol and the copy numbers were normalized
based on the standard curve generated from those three con-
trol samples. For quantitative real time RT-PCR, 1.189 and
0.084 were used as the cutoff for gain and loss, respectively.
Statistical analyses
Our study aimed to determine the following issues; 1) whe-
ther any correlations could be drawn between the mean num-
ber of chromosomal alterations (gain or loss) and the TNM
cancer stage; 2) whether gene pairs could be significantly cor-
related with clinicopathological variables (sex, age, lymph
node status, metastatis status and TNM cancer stage); and 3)
whether gene pairs exhibited concordant behavior, according
to the results of categorical analyses. 
We utilized several statistical analytical techniques to veri-
fy our results. Possible correlations between clinicopathologi-
cal variables (sex, age, lymph node status, metastasis status
and TNM cancer stage) and the copy-number status of each
of the spots were evaluated via two-sided Fisher exact tests.Genetic Alterations in Primary Gastric Carcinomas 659
We employed one-way ANOVA in our comparisons of the
differences in the mean number of chromosomal alterations
(gain or loss) between TNM tumor stages. Correlations bet-
ween array-CGH results and RT-PCR measurements were
assessed via Pearson’s tests, and the concordance rates between
the two tests were determined using conventional formulas.
p values of <0.05 were considered to be significant.
RESULTS
The frequency of genetic alteration determined by array
CGH
Table 1 displays the summary of the results of array CGH
analysis and the clinicopathological data obtained from 28
gastric cancer patients. A total of 1,440 qualified array BAC
clones were applied for the purpose of data analysis, and we
attempted to determine the amount of copy number chan-
ges occurring in the DNA sequences. All of our patients (28
of 28 cases) manifested chromosomal alterations (gain and
loss) in more than one clone. Copy number gains were deter-
mined to be more frequent than losses in the majority of cases.
The mean number of gained clones was 73.2 (range, 5-221),
and the mean number of lost clones was 52.5 (range, 0-322).
Relationships between TNM tumor stage and the mean num-
ber of chromosomal alterations (gain or loss) are shown in
Fig. 3. The number of chromosomal alterations in the stage
IV group (3/28) differed significantly from the number of
chromosomal alterations detected in the other cancer stage
groups. We determined there to be a statistically significant
correlation between the number of lost chromosomal regions,
and tumor stage (p=0.000). 
The most frequent aberrations in terms of copy number
gains (≥30% of patients) were encountered at the following
locations: 1p, 5p, 7q, 8q, 11p, 16p, 20p and 20q. The most
frequently detected losses (≥25% of patients) occurred at
1p, 2q, 4q, 5q, 7q, 9p, 14q, and 18q, as is shown in Table 2
and 3. An overview of all of the chromosomal aberrations is
displayed in Fig. 1. Representative examples of high-resolu-
tion analyses of a few of these frequently-detected aberrations
are shown in Fig. 2. 
Associations between chromosomal alterations and clini-
copathological variables 
We explored the statistical relationship between chromo-
somal alterations and clinicopathological variables, and the
*Alterations were defined by log2 ratio thresholds of 0.25 for copy num-
ber gain. Using this threshold, we generated a frequency Table. In this
Table, the 16 clones most frequently exhibiting gains are shown.
Chromoso- Clone Genes  contained
Cases with 
copy number
mal band name in clones
gain (%)*
1p36.33 CDC2L2 LOC400730, SLC35E2 23 (82.1)
7q35 TIM1 OR2A9P 21 (75.0)
11p15.4 11p terminal KCNQ1, CDKN1C, KCNQ1DN, 19 (67.9)
SLC22A1LS, SLC22A18
CYHR1, KIFC2, FOXH1
8q24.3 REC Q4 PPP1R16A, GPT, LOC113655, 17 (60.1)
RECQL4
1p36.32 p73 WDR8, TP73 12 (42.9)
16p13.3 TSC2 TSC2, PKD1, TRAF7, RAB26 12 (42.9)
20q13.32 PCK1 PCK1, ZBP1, TMEPAI 12 (42.9)
20p11.21 PYGB ENTPD6, PYGB, C20orf22, PPIAP212 (42.9)
5p15.33 5p terminal CRR9, LOC401169, SLC6A3 11 (39.3)
11q12.2 SHGC-81124 FLJ20847, PGA5 11 (39.3)
8q24.22 WISP1 WISP1, NDRG1 10 (35.7)
10q26.2 10q terminal 10 (35.7)
3p21.31 BAP1 PPP2R5CP, BAP1, PHF7,  10 (35.7)
LOC56920, TNNC1, NISCH
17q25.3 17q terminal FLJ40457 9 (32.1)
20q12 stSG55010 MAFB 9 (32.1)
20q13.33 SOX18 KIAA1196, SAMD10, C20orf14, 9 (32.1)
SOX18
Table 2. Most frequently gained regions detected by micro-
array comparative genomic hybridization in 28 gastric adenocar-
cinomas, together with candidate genes
*Alterations were defined by log 2 ratio thresholds of -0.25 for copy number
loss. Using this threshold, we generated a frequency Table. In this table,
the 19 clones most frequently exhibiting copy number loss are shown.
Chromoso- Clone Genes  contained
Cases with 
copy number
mal band name in clones
gain (%)*
2q21.1 stSG39658 LOC150516, LOC401002,  26 (92.9)
LOC285101, LOC401003
1p21.1 RP11-259N12 AMY2A, AMY1A 24 (85.7)
4q27 D4S427 24 (85.7)
5q21.1 D1S497 DPYD 18 (64.3)
7q32.3 stSG47389 FLJ40288, LOC401405 12 (42.9)
9p23 SHGC-140329 12 (42.9)
4q28.2 D4S852 11 (39.3)
1p21.3 D1S497 DPYD 9 (32.1)
4q21.21 FGF5 MGC35043 9 (32.1)
7q34 TCRB TRBV6-6, TRBV7-5, TRBV5-5,  9 (32.1)
TRBV6-7, TRBV7-6, TRBV5-6, 
TRBV6-8, TRBV7-7, TRBV5-7,
TRBV6-9, TRBV7-8, TRBV5-8,
TRBV7-9, TRBV13, TRBV10-3,
TRBV11-3, TRBV12-3, TRBV12-4
4p15.2 D4S404 9 (32.1)
14q31.1 TSHR TSHR, NMNATP 8 (28.6)
17q11.2 OMG NF1, OMG, EVI2B 8 (28.6)
18q21.33 SCCA1 SERPINB13, SERPINB4, SERPINB3 8 (28.6)
4p12 SHGC-83115 GABRG1 8 (28.6)
4q32.2 D4S1598 FSTL5 8 (28.6)
5q33.3 D5S1352 FLJ31951 8 (28.6)
4q23 MTP DKFZP434G072, RG9MTD2, MTP 7 (25.0)
18q21.1 DCC LOC390855, DCC 7 (25.0)
Table 3. Most frequently lost regions detected by microarray com-
parative genomic hybridization in 28 gastric adenocarcinomas,
along with candidate genes660 J.U. Kang, J. Kang, K.C. Kwon, et al.
results of these investigations are summarized in Table 4. The
array CGH data were correlated with lymph node status (ne-
gative or positive), metastasis (negative or positive), differen-
tiation grade (well or moderate/poor), TNM tumor stage (I,
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Fig. 1. Frequency of chromosomal copy number change in 28 gastroesophageal tumors. Gains and losses are shown as green and red
bars, respectively, indicating the overall chromosomal copy number aberrations in the examined gastroesophageal tumors.
Gain-total
Loss-total
1   1    1   1    1   2   2    2   2   3   3    3   3 4   4 5    5  5    6 6 6 7 7 7   7    8 8 9 9  10 10 10 11 11 11 12 12 1313 14 15 15 16 17 17 17  18 19 19 2021 21 22 22
WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated. 
*Alterations were defined by log2 ratio thresholds of 0.25 for copy number gain, -0.25 for loss; 
� Fisher Exact’s-test.
Lymph node
Absent Present
Total p-value
�
9p23 loss 0.009
+ 2* (15.4) 10 (66.7) 12/28 (42.9)
- 11 (84.6) 5 (33.3) 16/28 (57.1)
14q31.1 loss 0.038
+ 1 ( 7.7) 7 (46.7) 8/28 (28.6)
- 12 (92.3) 8 (53.3) 20/28 (71.4)
Table 4. Specific regions significantly associated with clinicopathological variable
Metastasis
Absent Present
Total p-value
�
4q23 loss 0.038
+ 4 (16.7) 3 (75.0) 7/28 (25.0)
- 20 (83.3) 1 (25.0) 21/28 (75.0)
4q28.2 loss 0.016
+ 7 (29.2) 4 (100.0) 11/28 (39.3)
- 17 (70.8) 0 (0.0) 17/28 (60.7)
TNM Stage
I II III IV
Total p-value
4q23 loss 0.017
+ 1 (12.5) 2 (20.0) 1 (14.3) 3 (100) 7/28 (25.0)
- 7 (87.5) 8 (80.0) 6 (85.7) 0 (0.0) 21/28 (75.0)
9p23 loss 0.023
+ 2 (25.0) 2 (20.0) 5 (71.4) 3 (100) 12/28 (42.9)
- 6 (75.0) 8 (80.0) 2 (28.6) 0 ( 0.0) 16/28 (57.1)
14q31.1 loss 0.031
+ 1 (12.5) 2 (20.0) 2 (28.6) 3 (100) 8/28 (28.6)
- 7 (87.5) 8 (80.0) 5 (71.4) 0 ( 0.0) 20/28 (71.4)
18q21.1 loss  0.014
+ 1 (12.5) 0 (0.0) 4 (57.1) 2 (66.7) 7/28 (25.0)
- 7 (87.5) 10 (100) 3 (42.9) 1 (33.3) 21/28 (75.0)
20q12 gain 0.050
+ 1 (12.5) 3 (30.0) 2 (28.6) 3 (100) 9/28 (32.1)
- 7 (87.5) 7 (70.0) 5 (71.4) 0 (0.0) 19/28 (67.9)
Age (yr)
<70 70+
Total p-value
17q25.3 gain 0.039
+ 1 (8.3) 8 (50.0) 9/28 (32.1)
- 11 (91.7) 8 (50.0) 19/28 (67.9)
Sex
Male Female
Total p-value
8q24.3 gain 0.022
+ 16 (72.7) 1 (16.7) 17/28 (60.7)
- 6 (27.3) 5 (83.3) 11/28 (39.3)
Differentiation
WD/MD PD
Total p-value
4q15.2 loss 0.016
+ 1 (7.7) 8 (53.3) 9/28 (32.1)
- 12 (92.3) 7 (46.7) 19/28 (67.9)
4q21.21 loss 0.016
+ 1 (7.7) 8 (53.3) 9/28 (32.1)
- 12 (92.3) 7 (46.7) 19/28 (67.9)
4q28.2 loss 0.024
+ 2 (15.4) 9 (60.0) 11/28 (39.3)
- 11 (84.6) 6 (40.0) 17/28 (60.7)
14q31.1 loss 0.038
+ 1 (7.7) 7 (46.7) 8/28 (28.6)
- 12 (92.3) 8 (53.3) 20/28 (71.4)
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II, III, IV), gender (male or female), and age (<70 or 70+ yr).
Tumors in which we detected a loss at 9p23 (66.7%) or at
14q31.1 (46.7%) tended to test lymph node metastasis. A
significant level of correlation was also determined to exist
between a loss at 4q23 or 4q28.2 and metastasis (p=0.038,
p=0.036). The number of chromosomal alterations detected
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Fig. 2. Examples of microarray CGH results for four of the most frequently observed common regions. Whole genome profiles (A and D) are
shown in the upper portion, and individual chromosome profiles (B, C, E and F) are shown in more detail below the profile of the entire ge-
nome. A representative chromosome profile, showing high-level amplifications from 3p14.2 (B) and 20q12 (C) in patient 18, and loss at
10q24.32 (E) and 14q31.1 (F) in patient 21.
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was found to be higher in metastatic tumors than in tumors
without metastasis. A gain at 20q12, as well as losses at 4q23,
9p23, 14q31.1, or 18q21 were all related to the TNM tumor
stage. The number of chromosomal alterations exhibited a
tendency to increase directly with TNM stage. Furthermore,
losses at chromosomal locations 4q15.2, 4q21.21, 4q28.2 or
14q31.1 were associated significantly with histological grade
of differentiation, and a gain at 8q24.3 was significantly cor-
related with gender (p=0.02; 72.7% tumors showing 8q24
gain were from male patients). A gain at 17q25.3 was signifi-
cantly associated with age (p=0.039, 50% of tumors exhibit-
ing a gain at 17q25.3 were from patients who were more
than 70 yr old). 
Comparison of gene expression between array CGH
and real time PCR
Results of the array CGH trials were confirmed using quan-
titative real-time RT-PCR. For the purpose of validation, genes
were randomly selected from among the group of genes that
correlated significantly with clinicopathological parameters.
These selected genes were as follows: MAFB at 20q12 and
TSHR at 14q31.1. The MAFB gene was employed as a
representative amplified gene, and TSHR was chosen as an
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example of a deleted gene. We compared the gene expression
values generated by the two methods for each gene. In 75.0%
of the cases (21 of 28), the array-CGH data were consistent
with the quantitative real-time PCR data for the MAFB gene.
When using the TSHR gene, the two data sets were concor-
dant in 71.4% (20 of 28) of cases. We also analyzed correla-
tion between real-time RT-PCR and array-CGH. The Pear-
son’s correlation coefficient of each gene was as follows: MAFB
0.750* (p=0.000) and TSHR 0.631* (p=0.000). The compar-
ison of gene expression values determined by both methods
for MAFB and TSHR is shown in Fig. 4. 
DISCUSSION
Gastric carcinogenesis is a complex and multifactorial pro-
cess, and is associated with a multiplicity of etiologies and
genetic alterations. Chromosomal instability in cases of gas-
tric carcinoma appears to constitute a principal mechanism
of genetic damage, as has been shown in a host of classical
CGH studies which revealed a variety of chromosomal abnor-
malities (2-7). However, conventional CGH is characterized
by limited sensitivity and resolution, primarily because of its
substantial dependence on the morphology of the metaphase
chromosomes. Due to this significant limitation, this method
cannot be used to pinpoint the exact site of an amplicon (10).
Microarray-based CGH (array CGH), however, is a more
sensitive technique, which was designed specifically for this
purpose. In this technique, individual clones in arrays, rather
than whole genomes as metaphases, can be hybridized with
genomic DNA, allowing for the detection of dosage changes,
with a resolution as precise as 0.2 to 0.4 Mb (16). The primary
biological value inherent in high-resolution array CGH is
its ability to detect small amplicons and deletions, which in
many cases, appear to harbor specific oncogenes and tumor
suppressor genes (17). In this study, we used a BAC array
clone for CGH, in order to screen for high-resolution DNA
copy number changes and to precisely identify amplifications
across the entirety of the human genome, at an average reso-
lution of 2.3 Mb. 
The most frequently-detected gains and losses were deter-
mined to occur on chromosome 1, and in particular, 1p (gain:
82%, loss: 86%). Minimal regions of gain were found at
1p36.11-p33. This region includes the p73 gene. Increased
p73 expression has been previously noted in cases of gastric
carcinoma, and this has been correlated with the progression
of tumors (17). Furthermore, the p73 protein often detected
in gastric tumor tissue was known to be the wild-type (19).
In our present study, we detected the amplification of p73
(1p36.32) in 43% (12/28) of tumors in advanced stages. This
would appear to support the hypothesis that increases in the
generation of p73 may constitute a passive process, which is
secondary to the increased copy numbers of the gene (20). One
of the more interesting findings of this study involved the
consistent loss of DNA copy numbers at 1p, with a minimal
region being detected at 1p12-p31.1. In particular, 24 tumors
(86%) manifested a loss at 1p21.1 and a loss at 1p21.3 (32%).
Losses at 1p have also been repeatedly detected and reported
in previous CGH studies (2, 21), but at far lower frequencies
than were found in our study. Moreover, patients whose tumors
demonstrated LOH at 1p had significantly shorter survival
(p=0.017) than those patients whose tumors did not (22). This
indicates that aberrations in these regions, may be involved
in a nonrandom manner in the cytogenetic progression of gas-
tric carcinomas. However, in this present study, we could not
reach any significant differences between the loss of short arm
of chromosome 1 and clinopathological variables.
A gain at 7q was the second most frequently encountered
aberration, but was not statistically significant when corre-
lated with the clinicopathological factors assessed in our study.
Previous analyses have determined that this region contains
growth factor-related genes which may be associated with
chromosomal instability, and which this could not be statis-
tically significantly correlated with the clinicopathological
factors assessed in our study. Previous analyses have determin-
ed that this region contains growth factor-related genes which
may be associated with chromosomal instability, which may
in turn accelerate the progression of a tumor from early to
advanced stages (11). 
We noted a gain at 20q with fairly high frequency, with a
minimal region occurring at 20q11.2-q13.1. In particular,
a gain at 20q12 was correlated significantly with the stage of
TNM tumors. Multiple regions of low and high-level copy
number gains at 20q were significantly correlated with poor
clinical prognoses, and appear to contribute to the cancer phe-
notype, especially with regard to the aspects of immortaliza-
tion, genome instability, apoptosis, and increased prolifera-
tion (23). Several previously-undertaken CGH studies have
identified the 20q region as the most frequent site of DNA
gains in cases of gastric cancer (5, 11). Candidate genes at 20q
12-13 include BTAK (20q13), AIB1 (20q12), TOP1 (20q12-
13.1), NABC1 (20q13.2), and CYP24 (20q13.2) (16). The
expression of all of these genes at 20q12-13 appears to be reg-
ulated not only by amplification, but also by several other
mechanisms, including transcriptional activation. 
DNA copy number gains at 8q region were also encoun-
tered with fairly high frequency. Gains at 8q24.3 were 60%
(17/28), and four cases focused on 8q23-24, the region in
which the oncogene c-MYC is located. This would appear to
suggest that some genes on 8q, most notably 8q23-24, might
facilitate the tumorigenesis of gastric cancer (24). In fact, the
clones positioning this region have been end-sequenced and
we confirmed the exact location using FISH (data not shown).
These clones were also used to amplify the c-MYC gene via
PCR amplification, followed by direct sequencing, in order
to exactly identify the c-MYC locus.  
The most striking finding of this study involves the losses
detected at the 4q and 14q regions. Losses at 4q23 and 4q28664 J.U. Kang, J. Kang, K.C. Kwon, et al.
were associated with increased malignant gastric cancer behav-
ior, and were significantly correlated with advanced clinical
stage, metastasis, and poor differentiation. The shared areas
of genetic deletion indicate that the genes which are inacti-
vated at these loci normally exert regulatory effects on the
behavior of cells in various states of differentiation (25). The
loss of the long arm of chromosome 4 has been previously
recognized as a common occurrence in tumors occurring in
the gastroesophageal junction (25), lung (26), kidney (27),
and breast (28). However, no genes have yet been confident-
ly implicated in the deletions in the 4q region, and no con-
sistently encountered genetic defects have been identified
which can be used to predict clinical outcomes. Therefore,
further study with larger numbers of well-characterized pri-
mary tumors will be required in order to determine the tar-
get genes which are related to this region. 
Losses at 14q31.1 were correlated significantly with TNM
cancer staging and differentiation. This result is largely con-
sistent with the findings of previously undertaken molecular
studies, in which losses at 14q31-32.1 were frequently enco-
untered in cases of gastric carcinoma (29), and TSHR (14q31)
and AKTI (14q32.3) were put forward as candidate tumor
suppressor genes (TSGs) for stomach cancer (29). A loss at
14q by LOH has also been reported as one of the early events
in the carcinogenesis of both the gastric and biliary tract (30).
Loss at 9p23 has been correlated significantly with lymph
nodes invasion and  TNM tumor stage. TNM tumor stage
has, until now, been recognized as the most relevant prognos-
tic determinant (31), and the loss of chromosome 9p has been
reported to occur more frequently in cases of gastric cancers
that are relapsed or histologically malignant (32). A potential
tumor suppressor gene, p16 (INK4; 9p21), might be involved
to some degree in this genomic aberration. Recently, alter-
ations of CDKN2A at 9p21 have been confidently implicat-
ed in poorer prognoses in cases of gastric cancer, particularly
with regard to benign and borderline cases (33). 
According to our results, 18q21.33 (bcl2) and 18q21.1
(DCC) were frequently observed to exhibit losses, 28.6% and
25.0% respectively. Losses at 18q21.1, in particular, were
correlated significantly with TNM tumor staging. Several
candidate genes on 18q, Smad2 (18q21), Smad4 (18q21.1),
and bcl2 (18q21.3) have previously been mapped to this chro-
mosome (2). Our previous study showed that LOH at the
DCC locus (18q21.1) is a frequently encountered character-
istic of gastric cancer (30). In order to more reliably validate
the array-CGH data, we conducted quantitative real-time
RT-PCR on selected genes, and our results were concordant
within the same specimens. 
In summary, this study identified a series of specific ampli-
fied or deleted regions which could be clearly correlated with
clinical variables which had not been previously emphasized.
The most prominent finding of this study involved the loss
of 4q and 14q, which were significantly linked to malignant
aggravation and metastasis. Additional evaluations of the
genes within these regions might provide us with valuable
clues in the hunt for genes which can be associated with gas-
tric carcinoma.
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